Recent evidences indicate that ILF2 is highly expressed in non-small-cell lung cancer, glioma, lymphoma, leukemia, and cervical cancer, and high expression of ILF2 is associated with poor clinical outcome [12–15]. This evidence concerns the gene ILF2 and non-small cell lung carcinoma.